Aeglea BioTherapeutics, Inc.’s $60 Million Common Stock And Pre-Funded Warrants Offering

Davis Polk advised the joint book-running managers in connection with a $60 million SEC-registered common stock and pre-funded warrants offering by Aeglea BioTherapeutics, Inc. The common stock is listed on the NASDAQ Global Market under the symbol “AGLE.”

J.P. Morgan, Evercore ISI and H.C. Wainwright & Co. acted as underwriters in the deal.

Based in Austin, Texas, Aeglea is a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer.

The Davis Polk corporate team included partner Bruce K. Dallas and associates Emily Roberts and Stephanie Y. Cheng. The tax team included partner Rachel D. Kleinberg and associate Rebecca A. Rosen. The intellectual property and technology team included partner David R. Bauer and associate Yifu Chen.

Involved fees earner: David Bauer – Davis Polk & Wardwell; Yifu Chen – Davis Polk & Wardwell; Stephanie Cheng – Davis Polk & Wardwell; Bruce Dallas – Davis Polk & Wardwell; Rachel Kleinberg – Davis Polk & Wardwell; Emily Roberts – Davis Polk & Wardwell; Rebecca Rosen – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: Evercore Partners; H.C. Wainwright & Co.; JP Morgan;


Author: Ambrogio Visconti